EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Vergleichsstudie

Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis

Benjamin Terrier iD, Grégory Pugnet iD, Claire de Moreuil, Bernard Bonnotte, Ygal Benhamou, Dominique Chauveau, Marie-Charlotte Besse iD, Pierre Duffau, Nicolas Limal, Antoine Néel, Geoffrey Urbanski, Noémie Jourde-Chiche iD und 28 weitere

Annals of Internal Medicine · 2025-09 · 178 (9) · 1249-1257

DOI: 10.7326/annals-24-03947 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Annals of Internal Medicine, 2025-09. Verfasst von Benjamin Terrier und 39 weiteren Autor:innen. Beteiligte Einrichtung: National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), and Université Paris C…. Hauptthemen laut MEDLINE: Rituximab, Glucocorticoids, Granulomatosis with Polyangiitis, Immunosuppressive Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is an eosinophilic antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Rituximab has emerged as the standard of care in other types of ANCA-associated vasculitis, but controlled studies on its use in EGPA are yet lacking. OBJECTIVE: To compare rituximab with conventional strategy for the induction of remission in patients with EGPA. DESIGN: Phase 3, multicenter, randomized, controlled, double-blind, superiority trial. (ClinicalTrials.gov: NCT02807103). SETTING: France. PARTICIPANTS: Patients with a diagnosis of EGPA, newly diagnosed or relapsing disease at the time of screening, with active disease defined as a Birmingham Vasculitis Activity Score (BVAS) of 3 or greater. INTERVENTION: Glucocorticoids plus rituximab (1 g 2 weeks apart) compared with the conventional strategy (glucocorticoids alone or in combination with cyclophosphamide in severe forms) for induction of remission. MEASUREMENTS: The primary end point was remission defined as a BVAS, version 3, of 0 and a prednisone dose of 7.5 mg/d or less at day 180. Secondary end points included duration of remission during the study, average daily glucocorticoid dose, and safety. RESULTS: = 0.41). All relapse and major relapse rates were similar between the 2 groups. There was no statistically significant difference in the average daily glucocorticoid dose and no statistically significant differences in the rates of adverse events between the treatment groups. LIMITATION: Design not appropriate to answer the question of equivalence between rituximab and cyclophosphamide in patients with severe EGPA. CONCLUSIONS: Rituximab was not superior to a conventional remission induction strategy in EGPA. PRIMARY FUNDING SOURCE: French Ministry of Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabGlucocorticoidsGranulomatosis with PolyangiitisImmunosuppressive AgentsImmunologic FactorsHumansMaleFemaleRemission InductionMiddle AgedDouble-Blind MethodAdultDrug Therapy, CombinationCyclophosphamidePrednisoneAged

Substanzen

RituximabGlucocorticoidsCyclophosphamidePrednisoneImmunosuppressive AgentsImmunologic Factors

Autor:innen und Institutionen

  • National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), and Université Paris Cité, Paris, France (B.T., L.G., X.P.).
  • Department of Internal Medicine and Clinical Immunology, CHU Toulouse Rangueil, Toulouse, France (G.P., D.C.).
  • Department of Internal Medicine, CHU Brest, Brest, France (C.deM.).
  • Department of Internal Medicine, University Hospital Dijon-Bourgogne, and EFS, INSERM U1098, UMR RIGHT, Bourgogne Franche-Comté University, Dijon, France (B.B.).
  • Department of Internal Medicine, CHU Rouen, Rouen, France (Y.B.).
  • Department of Internal Medicine, CHU Tours, Tours, France (M.-C.B.).

ORCID-Profile: Benjamin Terrier, Grégory Pugnet, Marie-Charlotte Besse, Noémie Jourde-Chiche, Julien Campagne, Arsène Mekinian, Nicolas Schleinitz, Anne-Laure Fauchais, Yurdagul Uzunhan, Laurent Chiche, Pierre Charles, Antoine Dossier, Loïc Guillevin

Zitieren

APA

Terrier, B., Pugnet, G., de Moreuil, C., Bonnotte, B., Benhamou, Y., Chauveau, D., Besse, M. C., Duffau, P., Limal, N., Néel, A., Urbanski, G., Jourde-Chiche, N., Martin-Silva, N., Campagne, J., Mekinian, A., Schleinitz, N., Ackermann, F., Fauchais, A. L., Froissart, A., …, & French Vasculitis Study Group (2025). Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis. Annals of Internal Medicine, 178(9), 1249-1257. https://doi.org/10.7326/annals-24-03947

Vancouver

Terrier B, Pugnet G, de Moreuil C, Bonnotte B, Benhamou Y, Chauveau D, et al. Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis. Annals of Internal Medicine. 2025;178(9):1249-1257. doi:10.7326/annals-24-03947

BibTeX
@article{Terrier2025,
  author = {Terrier, Benjamin and Pugnet, Grégory and de Moreuil, Claire and Bonnotte, Bernard and Benhamou, Ygal and Chauveau, Dominique and Besse, Marie-Charlotte and Duffau, Pierre and Limal, Nicolas and Néel, Antoine and Urbanski, Geoffrey and Jourde-Chiche, Noémie and Martin-Silva, Nicolas and Campagne, Julien and Mekinian, Arsène and Schleinitz, Nicolas and Ackermann, Felix and Fauchais, Anne-Laure and Froissart, Antoine and Le Gallou, Thomas and Uzunhan, Yurdagul and Viallard, Jean-François and Bérezné, Alice and Chiche, Laurent and Taillé, Camille and Direz, Guillaume and Durel, Cécile-Audrey and Godmer, Pascal and Trad, Salim and Lambert, Marc and de Menthon, Mathilde and Quéméneur, Thomas and Cadranel, Jacques and Charles, Pierre and Dossier, Antoine and Jilet, Léa and Guillevin, Loïc and Abdoul, Hendy and Puéchal, Xavier and French Vasculitis Study Group, French Vasculitis Study Group},
  title = {Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis},
  journal = {Annals of Internal Medicine},
  year = {2025},
  volume = {178},
  number = {9},
  pages = {1249--1257},
  doi = {10.7326/annals-24-03947}
}
Kostenlos starten →